Injectable Pricing & Rebate Tracker: Botox, Dysport, Jeuveau, Daxxify, Xeomin

Botox Cosmetic (onabotulinumtoxinA, AbbVie) remains the category leader by volume and holds the highest list price, typically $12–$15 per unit at wholesale depending on volume tier and rebate status. Dysport (abobotulinumtoxinA, Galderma) is priced lower per unit (roughly $3–$5 per unit) but requires 2.5–3× the units for equivalent effect, narrowing the cost-per-treatment gap. Jeuveau (prabotulinumtoxinA, Evolus) launched as a value play and trades at $4–$6 per unit wholesale. Daxxify (daxibotulinumtoxinA, AbbVie) commands a premium ($16–$20 per unit) justified by its claimed 6-month duration; adoption remains modest outside early-adopter practices. Xeomin (incobotulinumtoxinA, Merz) occupies a mid-market position ($6–$9 per unit) and appeals to practices managing neurotoxin resistance or seeking product rotation. Actual landed costs vary by practice size, rebate tier, and negotiated terms with group purchasing organizations (GPOs) or direct manufacturer agreements.

Allē (formerly Allergan Ascend Practitioner Program) is AbbVie's loyalty engine for Botox and Daxxify. The program operates on quarterly volume thresholds and growth metrics. Practices that hit defined unit minimums (e.g., 500–1,000 units of Botox per quarter, depending on tier) unlock rebates of $0.50–$2.00 per unit, applied as credits or direct payments. AbbVie recently introduced a quarterly Botox rebate for qualifying growth, rewarding practices that increase Botox volume quarter-over-quarter by a set percentage with additional per-unit credits. The mechanics: you report quarterly purchases to Allē, AbbVie calculates rebate eligibility, and credits post 30–60 days after quarter close. Practices must maintain active Allē enrollment and meet minimum purchase commitments to stay in higher tiers. Rebate tiers reset annually, so a practice's Q4 performance does not automatically carry into Q1 of the next year.

Aspire is Galderma's rebate program covering Dysport (neuromodulator), Radiesse (CaHA biostimulator), and other injectables. Aspire operates similarly to Allē: quarterly volume tiers unlock per-unit rebates. Dysport rebates typically range $0.30–$1.50 per unit depending on tier and growth achievement. Galderma has been aggressive in Q2–Q3 2026, raising guidance and signaling strong aesthetics revenue growth, partly driven by GLP-1 weight-loss drug demand (patients on semaglutide/tirzepatide seek facial rejuvenation to offset volume loss). This market tailwind has made Galderma competitive on rebate offers. Aspire also includes a digital dashboard for tracking purchases and rebate accrual in real time, reducing administrative friction. Like Allē, Aspire requires quarterly reporting and resets tier eligibility annually.

Evolus Rewards is Evolus's loyalty program for Jeuveau. Evolus has posted three consecutive quarters of positive adjusted EBITDA (Q2 2026) and raised full-year guidance, signaling operational confidence and ability to sustain rebate investment. Jeuveau rebates under Evolus Rewards range $0.75–$1.75 per unit for qualifying volume, with aggressive growth incentives to capture market share from Botox and Dysport. Evolus targets practices seeking lower per-unit acquisition cost and is willing to offer higher rebate percentages to practices that commit volume. Evolus Rewards also includes marketing co-op funds and practice-support resources (training, patient materials) bundled into the program. The program is newer and less mature than Allē or Aspire, so terms can be more flexible for high-volume practices willing to negotiate.

Landed cost = (list price per unit × volume purchased) − (rebate per unit × volume) − (GPO/negotiated discounts) ÷ total units. Example: 1,000 units of Botox at $14 list = $14,000. If you hit Allē tier 2 ($1.00/unit rebate), subtract $1,000 = $13,000 ÷ 1,000 = $13.00 landed cost per unit. If you sell that unit to patients at $12–$15 per unit (typical retail), your gross margin per unit is $0–$2.00 before staff, overhead, and facility costs. High-volume practices (5,000+ units/quarter) negotiate directly with manufacturers and can achieve landed costs of $8–$11 per unit on Botox, unlocking $3–$5 gross margin per unit. Small practices (500–1,000 units/quarter) often pay $12–$13 landed cost, leaving minimal margin unless they price aggressively or bundle injectables into package deals. Track your quarterly rebate accrual and compare it to your practice's patient pricing to model true profitability.

Quarterly rebate resets: Allē, Aspire, and Evolus Rewards all reset tier eligibility at the start of each calendar quarter. Plan Q1 purchasing strategy in December; don't assume Q4 rebate tier carries forward. Manufacturer pricing announcements: AbbVie, Galderma, and Evolus adjust list prices and rebate structures 2–4 times per year. Subscribe to manufacturer newsletters and check your account rep quarterly for updates. Growth incentives: All three programs reward quarter-over-quarter growth with bonus rebates. If you grew 10% Q1 vs. Q4, you may unlock an extra $0.25–$0.50/unit. Track your own volume trends to forecast rebate income. GPO negotiations: If your practice is part of a larger group or MSO, your GPO may have negotiated direct pricing that supersedes standard rebate tiers. Verify your actual cost basis with your group's procurement team. Competitive switching: Monitor competitor pricing and patient perception. If a local practice is offering Dysport at $10/unit and you're at $12/unit, a $0.50 rebate difference won't close the gap; you may need to adjust retail pricing or shift product mix.